Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0IAWOZ
ADC Name	JP2025011033A Ab2
Synonyms	Ab2 Click to Show/Hide
Organization	ELI LILLY AND COMPANY
Drug Status	Investigative
Antibody Name	Ab2	Antibody Info
Antigen Name	Nectin-4 (NECTIN4)	Antigen Info
Payload Name	Undisclosed
Therapeutic Target	Stimulator of interferon genes protein (STING1)	Target Info
Linker Name	Undisclosed

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Mean tumor colume&#177SEM	72.57&#17714.06	mm³	Undisclosed	Undisclosed
Mean tumor colume&#177SEM	124.95&#17710.32	mm³	Undisclosed	Undisclosed

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal inhibitory Concentration (lC50)	0.0473	nM	CVCL_1494	Minimally invasive lung adenocarcinoma
Half Maximal inhibitory Concentration (lC50)	0.07	nM	CVCL_0554	Bladder carcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Mean tumor colume&#177SEM	72.57&#17714.06 mm³	High nectin-4 expression (nectin-4 +++)
Method Description	Immune compromised female mice between 5-8 weeks of age with weight 18-20 grams were implanted unilaterally on the right flank with UM-UC-3 Nectin4 clone F7 cells with high nectin-4 expression, when tumors reached appproximately 150-250 mm^3, animals were matched by tumor volume into treatment or controls groups and dosing initiated (Day 0, n=8 per group). The test articles were given at a single dose (2 mg/kg) formulated with 5% dextrose. Tumors were measured biweekly until Day 40. Click to Show/Hide
In Vivo Model	UMUC3 Nectin-4 clone F7 xenograft model
Experiment 2 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Mean tumor colume&#177SEM	124.95&#17710.32 mm³	Moderate nectin-4 expression (nectin-4++)
Method Description	Female NSG mice between 5-6 weeks of age were injected subcutaneously withMDA-MB-468 cells with moderate nectin-4 expression, when tumors reached appproximately 150-250 mm^3, animals were matched by tumor volume into treatment or controls groups and dosing initiated (Day 0, n=8 per group). The test articles were given at a single dose (2 mg/kg) formulated with 5% dextrose. Tumors were measured biweekly until Day 71. Click to Show/Hide
In Vivo Model	MDAMB468 xenograft model

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.0473 nM	Positive nectin-4 expression (nectin-4+++/++)
Method Description	ADCs were tested in NCI H1781 cells, and were added at final working concentration from 200 nM, 1:4 serially diluted in culture medium for 5 days.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H1781 cells		CVCL_1494
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.07 nM	Positive nectin-4 expression (nectin-4+++/++)
Method Description	ADCs were tested in T24-human nectin-4 clone 108 cells, and were added at final working concentration from 200 nM, 1:4 serially diluted in culture medium for 5 days.
In Vitro Model	Bladder carcinoma	T24-human nectin-4 clone cells		CVCL_0554

References

Ref 1	Nectin-4 antibodies and antibody-drug conjugates